Literature DB >> 11567957

The effect on intraocular pressure of latanoprost once or four times daily.

C Lindén1, A Alm.   

Abstract

AIMS: To compare the effect on intraocular pressure (IOP) of latanoprost applied once daily with four times daily and to study if the difference persisted when treatment changed to once daily.
METHODS: IOP was followed in 28 healthy volunteers in a double masked randomised 52 day study. Latanoprost 50 microg/ml was administered once daily in one eye and four times daily in the other during 2 weeks. Subsequently both eyes received one daily drop for 2 weeks. After another 3 weeks without treatment, a single drop was instilled in each eye.
RESULTS: The IOP reduction on days 2 and 3 was greater in the eyes treated with four daily doses (p<0.01). During the following period there were no statistically significant differences between the eyes. After 3 weeks without treatment the IOP was lower than pretreatment (p<0.001). A single dose of latanoprost on day 50 resulted in a similar decrease in IOP in both eyes. Transient photophobia, mild flare, and/or a few cells occurred in 15 subjects. Two subjects were withdrawn because of photophobia and/or signs of anterior uveitis.
CONCLUSION: Latanoprost four times daily caused an IOP reducing effect which was similar to once daily dosing, except for the first 2 days of treatment when it was more effective. Transient photophobia, cells, and flare were common during the four dose regimen, but resolved spontaneously without cessation of treatment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11567957      PMCID: PMC1723731          DOI: 10.1136/bjo.85.10.1163

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  18 in total

1.  Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension.

Authors:  C B Camras; R A Schumer; A Marsk; J S Lustgarten; J B Serle; J Stjernschantz; L Z Bito; S M Podos
Journal:  Arch Ophthalmol       Date:  1992-12

2.  Latanoprost 0.005% and anterior segment uveitis.

Authors:  S L Smith; C A Pruitt; C S Sine; A C Hudgins; W C Stewart
Journal:  Acta Ophthalmol Scand       Date:  1999-12

3.  [Electron microscopy and immunohistochemical studies of the intraocular pressure lowering effect of prostaglandin F2 alpha].

Authors:  E Tamm; M Rittig; E Lütjen-Drecoll
Journal:  Fortschr Ophthalmol       Date:  1990

4.  A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.

Authors:  P Watson; J Stjernschantz
Journal:  Ophthalmology       Date:  1996-01       Impact factor: 12.079

5.  Morphological study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin F2 alpha.

Authors:  E Lütjen-Drecoll; E Tamm
Journal:  Exp Eye Res       Date:  1988-11       Impact factor: 3.467

6.  Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.

Authors:  A Alm; J Stjernschantz
Journal:  Ophthalmology       Date:  1995-12       Impact factor: 12.079

7.  Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens.

Authors:  S Nagasubramanian; G P Sheth; R A Hitchings; J Stjernschantz
Journal:  Ophthalmology       Date:  1993-09       Impact factor: 12.079

8.  Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study.

Authors:  A Alm; J Villumsen; P Törnquist; A Mandahl; J Airaksinen; A Tuulonen; A Marsk; B Resul; J Stjernschantz
Journal:  Ophthalmology       Date:  1993-09       Impact factor: 12.079

9.  Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes.

Authors:  C B Toris; C B Camras; M E Yablonski
Journal:  Ophthalmology       Date:  1993-09       Impact factor: 12.079

10.  Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol.

Authors:  A Alm; I Widengård; D Kjellgren; M Söderström; B Friström; A Heijl; J Stjerschantz
Journal:  Br J Ophthalmol       Date:  1995-01       Impact factor: 4.638

View more
  4 in total

1.  A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension.

Authors:  David Eveleth; Carla Starita; Charles Tressler
Journal:  BMC Ophthalmol       Date:  2012-05-18       Impact factor: 2.209

2.  Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension.

Authors:  Anne J Lee; Peter McCluskey
Journal:  Clin Ophthalmol       Date:  2010-07-30

3.  Effect of topical anti-glaucoma medications on late pupillary light reflex, as evaluated by pupillometry.

Authors:  Shakoor Ba-Ali; Birgit Sander; Adam Elias Brøndsted; Henrik Lund-Andersen
Journal:  Front Neurol       Date:  2015-04-29       Impact factor: 4.003

4.  Latanoprost with high precision, piezo-print microdose delivery for IOP lowering: clinical results of the PG21 study of 0.4 µg daily microdose.

Authors:  Louis R Pasquale; Shan Lin; Robert N Weinreb; James C Tsai; Robert L Kramm; Tsontcho Ianchulev
Journal:  Clin Ophthalmol       Date:  2018-11-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.